BidaskClub downgraded shares of Audentes Therapeutics (NASDAQ:BOLD) from a strong-buy rating to a buy rating in a report issued on Wednesday morning.
BOLD has been the topic of several other research reports. Zacks Investment Research cut Audentes Therapeutics from a hold rating to a sell rating in a report on Friday, November 17th. ValuEngine lowered Audentes Therapeutics from a hold rating to a sell rating in a research note on Friday, October 13th. Leerink Swann reaffirmed an outperform rating and set a $29.00 price target (up previously from $22.00) on shares of Audentes Therapeutics in a research note on Wednesday, November 15th. William Blair initiated coverage on Audentes Therapeutics in a research note on Tuesday, October 17th. They set an outperform rating and a $35.00 price target on the stock. Finally, Raymond James Financial initiated coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They set a market perform rating on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Audentes Therapeutics presently has an average rating of Hold and a consensus price target of $28.29.
Shares of Audentes Therapeutics (NASDAQ:BOLD) traded up $0.24 during trading hours on Wednesday, reaching $29.13. The company’s stock had a trading volume of 174,543 shares, compared to its average volume of 217,480. Audentes Therapeutics has a 52-week low of $13.90 and a 52-week high of $33.43.
In other news, SVP Mary Newman sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $26.84, for a total transaction of $268,400.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Suyash Prasad sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 761,500 shares of company stock worth $21,457,100. 47.30% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Audentes Therapeutics during the third quarter worth about $143,000. Nationwide Fund Advisors grew its holdings in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after buying an additional 6,384 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Audentes Therapeutics during the second quarter worth about $210,000. Rhumbline Advisers bought a new position in Audentes Therapeutics in the second quarter valued at approximately $252,000. Finally, Virtu KCG Holdings LLC bought a new position in Audentes Therapeutics in the second quarter valued at approximately $257,000. 78.99% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “BidaskClub Lowers Audentes Therapeutics (BOLD) to Buy” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/09/bidaskclub-lowers-audentes-therapeutics-bold-to-buy.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
What are top analysts saying about Audentes Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics Inc and related companies.